PULMO PHARMA
Pulmo Pharma was founded by graduates of the University of Technology Sydney (Australia), University of Rhode Island (USA), TU Munich (Germany), KU Leuven (Belgium), University of Tokyo (Japan), University of Tartu (Estonia), University of Oulu (Finland) and the University of Leicester (UK). We research pulmonary diseases & develop new therapies for patients suffering from hereditary and toxin caused lung diseases.
PULMO PHARMA
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2014-03-19
Address:
Hingham, Massachusetts, United States
Country:
United States
Website Url:
http://www.pulmo-pharma.com
Total Employee:
101+
Status:
Closed
Email Addresses:
[email protected]
Total Funding:
55 M USD
More informations about "Pulmo Pharma"
The History - Pulmopharma
Pulmopharma ApS was established back in November 2014. The technology itself was a spinoff from the parent company called LiquidVanity ApS, which holds the extensive basic patent for โฆSee details»
Home โ Pulmopharma
Our aim is that Puldium TM will became the gold standard treatment for all suspected fungi infections in the lungs since itโll fully eliminate most known variants. Puldium TM is delivered directly to the lungs using a standard jet โฆSee details»
Information โ Pulmopharma
PulmoPharma has so far been supported by public and private investors. The team behind PlumoPharma ApS has completed a pallet of proof-of-concept studies on various โฆSee details»
Pulmo Pharma - Funding, Financials, Valuation & Investors
Pulmo Pharma researches lung related diseases. Start Free Trial . Chrome ExtensionSee details»
PULMOPHARMA
25.983.106 natanael goncalves dos santos. cnpj 25.983.106/0001-83See details»
Pulmo Pharma - Drug pipelines, Patents, Clinical trials - Synapse
Last update 11 Jul 2024. Pulmo Pharma. Startups |See details»
DISTRIBUIDORA PULMOPHARMA (@distribuidora.pulmopharma)
637 Followers, 0 Following, 14 Posts - DISTRIBUIDORA PULMOPHARMA (@distribuidora.pulmopharma) on Instagram: "IMPORTADORES DE INSUMOS MÉDICOS โฆSee details»
Management | PulmoBioMed
Accomplished business developer in pulmonary field with 30+ years across entrepreneurial, small & large pharma including strategic consulting. Co-founder of speciality respiratory company โฆSee details»
Private Equity Round - Pulmo Pharma - 2017-06-24 - Crunchbase
Jun 24, 2017 Pulmo Pharma raised $20000000 on 2017-06-24 in Private Equity Round. New. Resources. Advanced Search. Start Free Trial . Talk With Sales ... Private Equity Round - โฆSee details»
About Us | Pulmovant
Prior to Pulmovant, Carlos was the Senior Vice President and Head of Program Management and Operations at Sonata Therapeutics (a Flagship Pioneering Company), and before that he served as the Vice President and Global โฆSee details»
Pulmo BioMed Co., Ltd.
Pulmo BioMed is committed to the research and development of new protein drugs with precise targets and patented technology. The aim of our product development is new protein drugs โฆSee details»
Company Development - About Us - Pulmo BioMed Co., Ltd.
Pulmo BioMed, established by JOYCOM Group in the year 2021, is a biotechnology pharmaceutical company focusing on new drug development. Dr. Le-Shin Chang serves as โฆSee details»
Pulmo Pharma: ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅๆถ
ไบ่งฃPulmo Pharmaๅ ฌๅธ็่ฏ็ฉ็ฎก็บฟ๏ผๆฒป็้ขๅ๏ผๆๆฏๅนณๅฐ๏ผไปฅๅๅฎ็ใSee details»
Pulmopharma | 011 2858-4498 | Sarandí - TodosNegocios
Puede contactar a Pulmopharma por teléfono al 011 2858-4498. La categoría principal de Pulmopharma es Salones de belleza.See details»
Group Organization - ํํ์ ์ฝ(์ฃผ)
Synergy effect created with HW respiratory products in PULMO and ENT Top down marketing through academic society and key opinion leaders Intensive call & marketing campaign for โฆSee details»
Development โ Pulmopharma
Infections and mortality caused by azole-resistant Aspergillus fumigatus are steeply increasing in several countries. To illustrate this, no effective cure against certain types of Aspergillus โฆSee details»
J&J-backed Pulmocide fills its lungs with $92M series C to fund โฆ
May 26, 2021 Pulmocide, targeting serious acute and chronic respiratory diseases, today breathed in an oversubscribed $92 series C as an IPO looks to be on the cards. | Pulmocide โฆSee details»
PulmoFlow DMF, CEP, Written Confirmations, FDF, Prices, Patents ...
PulmoFlow// PulmoFlow, Inc. is a newly established company currently focused on identifying unique opportunities in the field of respiratory indications with the aim to bring to market drug โฆSee details»
Pulmocide raises $30m for inhaled anti-infectives - pharmaphorum
Mar 20, 2017 A UK biotech company has raised $30 million to fund development of its treatments for respiratory infections. Privately-held Pulmocide is developing novel compounds โฆSee details»